Evidence map›Paper›PMID 32881379›Full record

ArticleAnnals of clinical and translational neurology2020

Neurodegeneration trajectory in pediatric and adult/late DM1: A follow-up MRI study across a decade.

Garazi Labayru, Antonio Jimenez-Marin, Esther Fernández, Jorge Villanua, Miren Zulaica, Jesus M Cortes, Ibai Díez, Jorge Sepulcre, Adolfo López de Munain, Andone Sistiaga

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Targeting Myotonic Dystrophy Type 1 with Metformin.International journal of molecular sciences · 2022
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Garazi LabayruPersonality, Assessment and psychological treatment department; Psychology Faculty, University of the Basque Country (UPV/EHU), San Sebastián, Gipuzkoa, Spain.ORCID 0000-0002-7304-320X
Antonio Jimenez-MarinBiocruces-Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain.
Esther FernándezOsatek, Donostia University Hospital, Donostia- San Sebastián, Gipuzkoa, Spain.
Jorge VillanuaOsatek, Donostia University Hospital, Donostia- San Sebastián, Gipuzkoa, Spain.
Miren ZulaicaNeuroscience Area, Biodonostia Research Institute, Osakidetza, Donostia-San Sebastián, Gipuzkoa, Spain.
Jesus M CortesBiocruces-Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain.
Ibai DíezGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0001-5769-0178
Jorge SepulcreGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Adolfo López de MunainNeuroscience Area, Biodonostia Research Institute, Osakidetza, Donostia-San Sebastián, Gipuzkoa, Spain.
Andone SistiagaPersonality, Assessment and psychological treatment department; Psychology Faculty, University of the Basque Country (UPV/EHU), San Sebastián, Gipuzkoa, Spain.
University of the Basque Country · ESBiogipuzkoa Health Research Institute · ESHarvard University · USBiomedical Research Networking Center on Neurodegenerative Diseases · ESIkerbasque · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo characterize the progression of brain structural abnormalities in adults with pediatric and adult/late onset DM1, as well as to examine the potential predictive markers of such progression.

methods21 DM1 patients (pediatric onset: N = 9; adult/late onset: N = 12) and 18 healthy controls (HC) were assessed longitudinally over 9.17 years through brain MRI. Additionally, patients underwent neuropsychological, genetic, and muscular impairment assessment. Inter-group comparisons of total and voxel-level regional brain volume were conducted through Voxel Based Morphometry (VBM); cross-sectionally and longitudinally, analyzing the associations between brain changes and demographic, clinical, and cognitive outcomes.

resultsThe percentage of GM loss did not significantly differ in any of the groups compared with HC and when assessed independently, adult/late DM1 patients and their HC group suffered a significant loss in WM volume. Regional VBM analyses revealed subcortical GM damage in both DM1 groups, evolving to frontal regions in the pediatric onset patients. Muscular impairment and the outcomes of certain neuropsychological tests were significantly associated with follow-up GM damage, while visuoconstruction, attention, and executive function tests showed sensitivity to WM degeneration over time.

interpretationDistinct patterns of brain atrophy and its progression over time in pediatric and adult/late onset DM1 patients are suggested. Results indicate a possible neurodevelopmental origin of the brain abnormalities in DM1, along with the possible existence of an additional neurodegenerative process. Fronto-subcortical networks appear to be involved in the disease progression at young adulthood in pediatric onset DM1 patients. The involvement of a multimodal integration network in DM1 is discussed.

Indexed as

Magnetic Resonance ImagingAdultAtrophyDisease ProgressionExecutive FunctionFemaleFollow-Up StudiesGray MatterHumansMaleMiddle AgedMyotonic DystrophyNeurodegenerative DiseasesNeuropsychological TestsWhite Matter

Identifiers

PMID32881379
PMCPMC7545612
OpenAlexW3081774849

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.